About Nuclear pore complex protein Nup205
Nuclear pore complex protein Nup205 (NUP205) is a protein
from Homo sapiens identified by UniProt accession
Q92621, 2012 residues long.
MolForge cross-references it against 0 known binders and
93 disease associations.
Target properties
| Protein name | Nuclear pore complex protein Nup205 |
|---|
| UniProt accession | Q92621 |
|---|
| Gene | NUP205 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 2012 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (93)
Diseases linked to this target (Open Targets).
- influenza · score 0.54
- HIV infection · score 0.54
- viral disease · score 0.53
- familial idiopathic steroid-resistant nephrotic syndrome · score 0.53
- Alzheimer disease · score 0.46
- neurodegenerative disease · score 0.46
- lysosomal storage disease · score 0.46
- Parkinson disease · score 0.46
- multiple sclerosis · score 0.46
- Histiocytosis · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q92621-F1 | alphafold | PREDICTED | 78.16 | — |
Amino-acid sequence (2012 residues)
MATPLAVNSA ASLWGPYKDI WHKVGNALWR RQPEAVHLLD KILKKHKPDF ISLFKNPPKN VQQHEKVQKA STEGVAIQGQ QGTRLLPEQL IKEAFILSDL FDIGELAAVE LLLAGEHQQP HFPGLTRGLV AVLLYWDGKR CIANSLKALI QSRRGKTWTL ELSPELASMT TRFTDELMEQ GLTYKVLTLV SQIDVNNEFE KLQRERGLGS EKHRKEVSDL IKECRQSLAE SLFAWACQSP LGKEDTLLLI GHLERVTVEA NGSLDAVNLA LLMALLYCFD ISFIEQSTEE RDDMIHQLPL LTEKQYIATI HSRLQDSQLW KLPGLQATVR LAWALALRGI SQLPDVTALA EFTEADEAMA ELAIADNVFL FLMESVVVSE YFYQEEFYIR RVHNLITDFL ALMPMKVKQL RNRADEDARM IHMSMQMGNE PPISLRRDLE HLMLLIGELY KKNPFHLELA LEYWCPTEPL QTPTIMGSYL GVAHQRPPQR QVVLSKFVRQ MGDLLPPTIY IPYLKMLQGL ANGPQCAHYC FSLLKVNGSS HVENIQGAGG SPVSWEHFFH SLMLYHEHLR KDLPSADSVQ YRHLPSRGIT QKEQDGLIAF LQLTSTIITW SENARLALCE HPQWTPVVVI LGLLQCSIPP VLKAELLKTL AAFGKSPEIA ASLWQSLEYT QILQTVRIPS QRQAIGIEVE LNEIESRCEE YPLTRAFCQL ISTLVESSFP SNLGAGLRPP GFDPYLQFLR DSVFLRFRTR AYRRAAEKWE VAEVVLEVFY KLLRDYEPQL EDFVDQFVEL QGEEIIAYKP PGFSLMYHLL NESPMLELAL SLLEEGVKQL DTYAPFPGKK HLEKAVQHCL ALLNLTLQKE NLFMDLLRES QLALIVCPLE QLLQGINPRT KKADNVVNIA RYLYHGNTNP ELAFESAKIL CCISCNSNIQ IKLVGDFTHD QSISQKLMAG FVECLDCEDA EEFVRLEEGS ELEKKLVAIR HETRIHILNL LITSLECNPP NLALYLLGFE LKKPVSTTNL QDPGVLGCPR TCLHAILNIL EKGTEGRTGP VAVRESPQLA ELCYQVIYQL CACSDTSGPT MRYLRTSQDF LFSQLQYLPF SNKEYEISML NQMSWLMKTA SIELRVTSLN RQRSHTQRLL HLLLDDMPVK PYSDGEGGIE DENRSVSGFL HFDTATKVRR KILNILDSID FSQEIPEPLQ LDFFDRAQIE QVIANCEHKN LRGQTVCNVK LLHRVLVAEV NALQGMAAIG QRPLLMEEIS TVLQYVVGRN KLLQCLHAKR HALESWRQLV EIILTACPQD LIQAEDRQLI IRDILQDVHD KILDDEAAQE LMPVVAGAVF TLTAHLSQAV LTEQKETSVL GPAEAHYAFM LDSCFTSPPP EENPLVGFAS IGDSSLYIIL KKLLDFILKT GGGFQRVRTH LYGSLLYYLQ IAQRPDEPDT LEAAKKTMWE RLTAPEDVFS KLQRENIAII ESYGAALMEV VCRDACDGHE IGRMLALALL DRIVSVDKQQ QWLLYLSNSG YLKVLVDSLV EDDRTLQSLL TPQPPLLKAL YTYESKMAFL TRVAKIQQGA LELLRSGVIV RLAQCQVYDM RPETDPQSMF GMRDPPMFIP TPVDRYRQIL LPALQLCQVI LTSSMAQHLQ AAGQVLQFLI SHSDTIQAIL RCQDVSAGSL QELALLTGII SKAALPGILS ELDVDVNEGS LMELQGHIGR FQRQCLGLLS RFGGSDRLRQ FKFQDDNVEG DKVSKKDEIE LAMQQICANV MEYCQSLMLQ SSPTFQHAVC LFTPSLSETV NRDGPRQDTQ APVVPYWRLP GLGIIIYLLK QSANDFFSYY DSHRQSVSKL QNVEQLPPDE IKELCQSVMP AGVDKISTAQ KYVLARRRLV KVINNRAKLL SLCSFIIETC LFILWRHLEY YLLHCMPTDS QDSLFASRTL FKSRRLQDSF ASETNLDFRS GLAIVSQHDL DQLQADAINA FGESLQKKLL DIEGLYSKVR SRYSFIQALV RRIRGLLRIS RN
Explore Nuclear pore complex protein Nup205 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets